Emergent BioSolutions (EBS) Misses Q1 EPS by 1c, Reaffirms Guidance
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.00 --0%
EPS Growth %: -31.3%
Financial Fact:
Income (loss) from operations: 35.48M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -31.3%
Financial Fact:
Income (loss) from operations: 35.48M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of $0.29, $0.01 worse than the analyst estimate of $0.30. Revenue for the quarter came in at $116.9 million versus the consensus estimate of $116.17 million.
Emergent BioSolutions reaffirmed guidance.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- Evercore ISI Starts Credo Tech (CRDO) at Outperform
- Goldman Sachs Upgrades China Resources Microelectronics Ltd (688396:CH) to Neutral
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
